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Background: Bone metastases are a signiﬁcant and undertreated clinical problem in patients with advanced lung
cancer.
Design: We reviewed the incidence of bone metastases and skeletal-related events (SREs) in patients with lung cancer
and examined the burden on patients’ lives and on health care systems. Available therapies to improve survival and
lessen the impact of SREs on quality of life (QoL) were also investigated.
Results: Bone metastases are common in lung cancer; however, owing to short survival times, data on the incidences
of SREs are limited. As with other cancers, the costs associated with treating SREs in lung cancer are substantial.
Bisphosphonates reduce the frequency of SREs and improve measures of pain and QoL in patients with lung cancer;
however, nephrotoxicity is a common complication of therapy. Denosumab, a recently approved bone-targeted
therapy, is superior to zoledronic acid in increasing the time to ﬁrst on-study SRE in patients with solid tumours,
including lung cancer. Additional roles of bone-targeted therapies beyond the prevention of SREs are under
investigation.
Conclusions: With increasing awareness of the consequences of SREs, bone-targeted therapies may play a greater
role in the management of patients with lung cancer, with the aim of delaying disease progression and preserving QoL.
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introduction
Lung cancer is the most common neoplasm worldwide, with
an estimated 1.61 million new cases reported in 2008 [1]. In
the European Union alone, lung cancer was responsible for
∼254 000 deaths, equating to 20.6% of cancer mortality
(Figure 1). Overall survival rates are poor, with data from 2000
to 2002 indicating 1- and 5-year relative survival expectations
for ∼37% and 12% of patients, respectively [2]. Non-small-cell
lung cancer (NSCLC) accounts for 80%–85% of all lung cancer
diagnoses [3], the majority of which present as late-stage
disease [4], primarily owing to the asymptomatic nature of
early disease.
Platinum-based combination chemotherapy prolongs
survival in patients with NSCLC who have a good performance
status and remains the ﬁrst-line standard of care [3]. Both
pemetrexed, for those with non-squamous NSCLC, and
erlotinib maintenance treatment prolong overall survival in
patients with advanced NSCLC whose disease has not
progressed immediately following platinum-based
chemotherapy [5, 6]. Other ‘individualised’ ﬁrst-line treatments
[e.g. monoclonal antibodies, such as bevacizumab, which
targets vascular endothelial growth factor (VEGF) [7], and
cetuximab, the epidermal growth factor receptor (EGFR) [8],
or the tyrosine kinase inhibitors (TKIs) erlotinib and geﬁtinib
[9–12]] have shown promise in some patients but have not
signiﬁcantly improved survival in overall populations.
As the life expectancy of individuals with lung cancer
increases, symptom control measures are growing in
importance. Therefore, physicians require an increased
awareness of bone metastases and the need for their early
management to prevent potentially debilitating and costly
skeletal complications.
We present an overview of the prevalence, impact and
treatment of bone metastases in lung cancer. In recent years,
bisphosphonates have been the mainstay of pharmacological
intervention for reducing the symptoms associated with bone
metastases and the impact of the disease on quality of life
(QoL). Bisphosphonates target the underlying cause of skeletal
morbidity by binding to the bone surface and inhibiting
osteoclast-mediated bone resorption. Bisphosphonates are,
however, associated with nephrotoxicity, which requires
monitoring and may necessitate initial dose adjustment and
withholding of doses. Therefore, combining bisphosphonates
with commonly used platinum-based chemotherapy as ﬁrst-
line treatment is complicated by the overlapping renal safety
proﬁles of the two therapies.
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Denosumab is a new treatment option with the potential to
improve QoL for patients with bone metastases secondary to
lung cancer. This agent binds to and neutralises receptor
activator of nuclear factor κB (RANK) ligand (RANKL), a key
molecule involved in osteoclast differentiation and survival
[13–15], thereby inhibiting bone resorption [16]. In metastatic
cancers involving the bone, denosumab has been shown to
suppress markers of bone resorption [17–19]. This fully
human monoclonal antibody, which targets the bone-
remodelling pathway, is not cleared by the kidneys and is
therefore not associated with the same problems as
bisphosphonates in patients with renal impairment.
bone metastases and skeletal-related
events
Lung cancer frequently spreads to bone, with metastases
evident at post-mortem in up to 36% of patients [20] and bone
marrow micrometastases found in 22%–60% of individuals
[21]. The bone microenvironment is exposed to many growth
factors and cytokines that provide a fertile ‘soil’ for cancer cells,
making bone a preferred site of metastasis in advanced cancer.
Individuals with lung cancer and bone metastases have poor
prognoses with median survival times from detection of
metastases typically measured in months [20]. Most patients
who develop bone metastases experience complications such as
hypercalcaemia, severe bone pain requiring palliative
radiotherapy or analgesics, pathological fractures, spinal cord
compression and bone instability requiring orthopaedic
surgery. The last four of these complications are collectively
known as skeletal-related events (SREs), although some
historical studies also included hypercalcaemia in this
grouping.
SREs are a complication of the unrestricted resorption of
mineralised bone by osteoclasts and result in signiﬁcant
morbidity, requiring frequent hospitalisation, outpatient visits
and reduced QoL [22, 23]. Unfortunately, screening and
treatment of asymptomatic bone metastases are not considered
necessary in clinical practice. Consequently, bone metastases
are often not diagnosed in individuals with NSCLC until they
cause substantial pain or an SRE [24]. It is therefore important
to raise both patient and physician awareness of bone
metastases in lung cancer. Furthermore, therapy should be
considered at the time of bone metastasis detection, before
debilitating pain develops and SREs are experienced. Positron-
emission tomography scans may be useful for early detection
of asymptomatic bone metastases [25–27]; however, recent
European Society for Medical Oncology (ESMO) guidelines
recommend a bone scan only if there is bone pain,
hypercalcaemia or elevated alkaline phosphatase levels [3].
Owing to the historically short survival time in patients with
NSCLC, reports of SRE frequency in this population are
limited to data from the placebo arm of a large clinical trial
[28, 29], retrospective studies from Asia [30–32] (Figure 2) and
a Serbian bone scintigraphy study [33].
In a large multinational, randomised, double-blind phase III
trial of zoledronic acid versus placebo in patients with bone
metastases secondary to lung cancer and other solid tumours
(except carcinomas of the breast and prostate) [28, 29], 46% of
individuals treated with placebo experienced at least one SRE
during the 21-month study, with an overall average of 2.71
SREs per year in the placebo arm [28]. A breakdown of the
types of SREs experienced is shown in Figure 2A. A
retrospective exploratory analysis revealed that before study
entry, 69% of all randomised patients had experienced at least
one SRE, and that these individuals had a higher risk of a
subsequent SRE than those with no previous SREs (odds ratio:
1.41). During the study, the median time to ﬁrst SRE among
the subgroup of patients who had previously experienced an
SRE and were subsequently randomised to placebo was ∼3.5
months [34].
The Serbian study retrospectively analysed 100 patients with
lung cancer who underwent bone scintigraphy during a 3-year
period (2003–2005) [33]. Bone metastases were conﬁrmed in
57% of patients, with suspicious ﬁndings recorded in 11% of
individuals [33].
Results from retrospective studies from Japan [30, 32] and
Korea [31] conﬁrmed these ﬁndings. In one Japanese study,
the charts of all patients with NSCLC treated from February
2002 to January 2005 at a single hospital were analysed for
disease stage [using the tumour–node–metastasis (TNM)
staging system], presence of bone metastases, frequency of
SREs and survival [32]. Of 230 assessable individuals, 70
(30.4%) had bone metastases during their treatment, consistent
with the frequency reported from autopsy studies [20]. Bone
metastases were evident at the time of initial diagnosis in 46 of
these 70 patients (65.7%) [32]. Moreover, of patients with bone
metastases, 50.0% experienced SREs, the most common of
which were radiotherapy to bone (34.3%) and hypercalcaemia
(20.0%; Figure 2A). Among 135 individuals with stage IV
NSCLC, 41.5% had bone metastases; 44.6% of those with bone
metastases experienced SREs (Table 1). Median survival time
was shorter (187 days) for patients with SREs than for those
without (366 days; Table 1), although this difference was not
statistically signiﬁcant.
The second Japanese study retrospectively analysed 642
patients with metastatic NSCLC treated from December 2000
to June 2006 and showed that median survival was 15.4
months [30]. First-line platinum-based chemotherapy was
given to 73.1% of patients, and 18.2% of patients were treated
with geﬁtinib. Only 6.6% of patients received the
bisphosphonate zoledronic acid. In total, 118 (18.4%) patients
Figure 1. Cancer-related mortality in the European Union in 2008. Data
represent estimated numbers of cancer deaths in females and males across
all ages (total deaths = 1 234 303). Data from GLOBOCAN 2008 v1.2 [1].
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experienced SREs (Figure 2A), 40.7% of which were within
6 months of starting ﬁrst-line antitumour therapy. A further
27.1% of individuals experienced an SRE 6–12 months after
commencing treatment. Multivariate analysis revealed that
men, patients with a performance status of 2–3 and those with
multiple bone metastases were at greatest risk of a ﬁrst SRE.
Finally, a more recent Korean retrospective study of 273
patients with bone metastases secondary to NSCLC treated
from January 2006 to March 2009 showed that 62.6% had at
least one SRE and 16.8% experienced multiple SREs [31].
Radiotherapy to bone was by far the most common SRE
reported (Figure 2B). Analysis of risk factors for SREs
suggested that long-term smoking, non-adenocarcinoma
tumours, poor performance status and no history of treatment
with EGFR TKIs were predictors for SREs [31]. Surprisingly,
only 20.9% of patients with bone metastases were receiving
bisphosphonates and only 6.6% received a bone-targeted agent
before experiencing an SRE.
why treat bone metastases and SREs?
Bone metastases are a signiﬁcant cause of morbidity in patients
with advanced cancer. The frequency of SREs varies across
tumour types, but on average, individuals experience an SRE
every 3–6 months [20]. These events typically occur around
periods of disease progression, becoming more frequent as the
disease becomes more extensive [20]. Owing to recent
advances in systemic treatment of NSCLC, the median survival
of patients with advanced disease has increased to ∼1 year.
This may give tumours more time to metastasise to bone, so
SREs may become a more common problem. Even with the
relatively short survival time for patients with NSCLC, a large
percentage will experience SREs. Moreover, once an individual
experiences a ﬁrst SRE, they are likely to experience subsequent
events, leading to a spiral of debilitating and costly bone
problems. Therefore, there is a need to consider treatments
that can reduce the risk of SREs.
pain and reduced QoL
Bone metastases and SREs are associated with signiﬁcant pain
and reduced QoL, with negative effects on day-to-day
functioning. Indeed, pain from bone metastases is the most
frequent form of pain reported by patients with cancer and is
often disproportionate to the extent of bone involvement [35].
The pain associated with bone metastases frequently
necessitates strong analgesia or palliative radiation. Strong
narcotics, such as morphine, are stigmatised by connotations of
addiction and their association with death [36], and therefore,
patients may be reluctant to use them. Furthermore, narcotics
Figure 2. Overview of the occurrence of SREs in patients with NSCLC. (A) Data from the placebo arm of a large clinical trial including patients with
NSCLC (Rosen et al. 2004 [28]) and two retrospective audits of patients with NSCLC in Japan (Tsuya et al. 2007 [32] and Sekine et al. 2009 [30]). (B) Data
from a retrospective audit of 273 patients with NSCLC and bone metastases in Korea [31]. NSCLC, non-small-cell lung cancer; SRE, skeletal-related event.
Table 1 Comparison of median survival times of patients with stage III or
stage IV NSCLC, with or without bone metastases and SREs
NSCLC stage Patients, n Median survival time (days)
Stage III
No bone metastases 81 314
≥1 bone metastases 14 298
Stage III + bone metastasesa
No SRE 4 255
≥1 SRE 10 240
Stage IV
No bone metastases 79 268
≥1 bone metastases 56 237
Stage IV + bone metastases
No SRE 31 366
≥1 SRE 25 187
Data from a retrospective audit of patients with NSCLC in Japan [32].
aFollowing initial treatment.
NSCLC, non-small-cell lung cancer; SRE, skeletal-related event.
[Copyright (2007), with permission from Elsevier]
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may suppress respiration, which is unwelcome in individuals
with lung cancer.
The pathophysiological mechanisms of pain in patients with
bone metastases have not been fully elucidated but may include
tumour-induced osteolysis, production of tumour growth
factors and cytokines, nerve inﬁltration, ion channel
stimulation and production of endothelins and nerve growth
factors in local tissues [20]. Bone metastases commonly occur
at the base of the skull, the vertebral column or pelvic and
femoral areas. Metastases at the base of the skull are associated
with cranial nerve palsies, neuralgias and headaches, while
vertebral metastases produce neck and back pain, with or
without neurological complications secondary to epidural
extension. Pelvic and femoral lesions produce pain in the lower
back and limbs, often associated with mechanical instability
and incident pain. Bone metastases can also result in
pathological fractures (most commonly of the ribs and
vertebrae), which cause pain and have a detrimental effect on
QoL [20]. Pathological fractures and spinal cord compression
impair mobility and functional independence.
Despite the prospect of severe pain and reduced QoL, there
are few data on patient-reported outcomes [37]. In an Italian
study of 1021 individuals enrolled in three randomised trials of
chemotherapy for NSCLC, QoL (using the European
Organisation for Research and Treatment of Cancer core
questionnaire and the lung cancer-speciﬁc module), analgesic
use and adequacy of pain management (using the Pain
Management Index) were assessed. Bone metastases were
present in 22% of patients and were associated with some
degree of pain in almost 75% of these cases [22]. Almost 50%
of participants reported that pain affected their daily activities
(30% a little, 16% quite a bit and 3% very much) and the
severity of pain was linearly correlated with decreases in QoL
scores; mean global QoL decreased from 64.9 for patients
without pain to 36.4 for those with severe pain (P < 0.001).
The study revealed that 82% of individuals reporting pain
received inadequate analgesia. Although analgesics may be
used to treat the symptoms of bone pain, they do not
address the underlying cause, and side-effects of opiates,
such as nausea and constipation, may be worse than
the pain itself [38]. Therefore, delaying the need to use
strong analgesics may be advantageous in patients with
lung cancer.
A Norwegian study evaluated pain, QoL, depression,
physical functioning and social functioning at the time of
enrolment into a randomised clinical trial of 157 oncology
outpatients with pain from bone metastases [39]. One aim of
the study was to determine which of the following were key
predictors of QoL: pain characteristics (i.e. severity, duration,
meaning of pain and perceived availability and efﬁcacy of pain
relief ), psychological distress (e.g. depression), physical
functioning and social functioning. Another aim was to
determine the extent to which all of these variables were
correlated. The results showed that ‘meaning of pain’ (patients’
perception of pain [40]) was signiﬁcantly correlated with all
the other variables, particularly pain intensity and duration.
The key factors that predicted QoL were depression, social
functioning and physical functioning, with depression proving
to be the most important of these [39].
cost
Cancer-related bone disease contributes signiﬁcantly to health
care costs. In 2004, the cost of metastatic bone disease in the
USA estimated by the National Institutes of Health was US
$12.6 billion or 17% of total oncology expenditure [41]. In this
analysis, the estimated number of patients with lung cancer
was 237 469, with an estimated metastatic bone disease rate
of 15.6%. The increase in expenditure following metastatic
bone disease diagnosis was ∼US$36 000 in commercially
insured patients with lung cancer when compared with a
matched-control group of patients who did not have metastatic
disease (P < 0.001).
An earlier retrospective analysis of patients identiﬁed in a
USA insurance claims database from 1995 to 2002 showed that
55% of 534 individuals with lung cancer and bone metastases
experienced one or more SRE, with a median survival time after
the ﬁrst SRE of only 4.1 months. On average, the ﬁrst SRE-
related claim was only 1.2 months after the diagnosis of bone
metastasis, again indicating that early intervention may yield the
most beneﬁt in terms of morbidity and cost saving [42]. The
estimated lifetime cost of treating patients who experienced one
or more SREs was ∼US$12000 per patient, with most of the cost
(80%) incurred in the 2 months after the ﬁrst claim for an SRE.
Most costs were associated with radiotherapy to bone (60%;
US$7247), but surgery to bone (21%; US$2519) and treatment
of fractures (15%; US$1743) were also a signiﬁcant burden
(Figure 3A). The breakdown of the costs according to the types
of services used by patients is shown in Figure 3B. This study
therefore shows that the economic burden of treating SREs
associated with bone metastases secondary to lung cancer is
substantial. Importantly, this study focused on costs that could
be directly attributed to SREs and did not consider peripheral
costs such as physician visits and outpatient procedures.
Therefore, it is likely to underestimate the true cost associated
with SREs. Further analysis of this study revealed that total
medical costs were US$48 173 greater for patients with an SRE
versus those without [43].
Finally, a more recently reported European study evaluated
the burden imposed by SREs on Spanish hospital resources
[23]. Admission rates (3-year incidence from 2003) due to
bone metastases were 156 per 1000 for patients with lung
cancer, increasing to 260 per 1000 following an SRE. This
study also examined admission rates and costs associated with
breast and prostate cancer; for these neoplasms, ﬁrst-admission
costs increased with the development of bone metastases and
SREs. The cost associated with a ﬁrst admission for lung
cancer (€4994) was higher than for metastatic bone disease
(€4227) or for an SRE (€4298); this may reﬂect the severity of
lung cancer at initial presentation, again highlighting the need
for increased awareness leading to earlier diagnosis.
Nevertheless, the cost of an SRE in patients with lung cancer
remains high.
current treatments for NSCLC and links
with renal and bone health
Combination chemotherapy is the standard of care for NSCLC.
Third-generation agents such as pemetrexed, vinorelbine,
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gemcitabine and taxanes (e.g. paclitaxel and docetaxel), as well
as TKIs (e.g. erlotinib and geﬁtinib) or monoclonal antibodies
(e.g. bevacizumab), are often combined with cisplatin or
carboplatin in selected patients [3]. However, doses may be
limited by the cumulative nephrotoxicity of the platinum-based
component [44]. A study in 400 patients with advanced solid
tumours treated with weekly high-dose cisplatin showed that
∼40% of patients experienced some level of nephrotoxicity
[45]. The cisplatin analogue carboplatin is less nephrotoxic
than cisplatin. However, a meta-analysis of nine NSCLC trials
(2968 patients) found that carboplatin was less effective than
cisplatin in terms of survival [46]. If platinum-based therapy is
contraindicated, single or combination use of third-generation
agents or TKIs may be considered, although studies generally
show lower response rates with these regimens than with
platinum-based therapies [3].
In contrast to treatment-induced bone loss associated with
the early treatment of patients with breast and prostate cancer,
the components of ﬁrst-line therapy for NSCLC may have
beneﬁcial effects on bone resorption. In vitro, cisplatin has
been shown to be effective against hypercalcaemia of
malignancy by exerting inhibitory effects on osteoclasts and
bone resorption [47]. Results from a recent study suggest that,
in addition to antitumour effects, geﬁtinib has inhibitory effects
on bone resorption [48]. In addition, treatment with the anti-
human VEGF antibody bevacizumab (with zoledronic acid)
inhibited the number of experimental bone metastases,
including osteoblastic changes in a murine model of human
lung cancer [49]. Clinical studies have also shown beneﬁts. In a
study examining the effect of chemotherapy on bone
metabolism in 30 individuals with stage III NSCLC, two
courses of combination mitomycin C, cisplatin and vinblastine
resulted in a signiﬁcant reduction in bone resorption (P < 0.05)
[50]. In patients with spinal metastases from lung cancer,
geﬁtinib was effective in reducing pain and inducing normal
bone formation [51].
Radiotherapy is also an important treatment to ease
symptoms in NSCLC [3]. As discussed above, it also plays a
key role in the management of bone metastases. Radiotherapy
can be considered following spinal cord compression and for
stabilisation following surgery associated with pathological
fractures.
In treatment of lung cancer, there is also precedence
that early palliative intervention is beneﬁcial. A recent study
demonstrated the value of early palliative care in the course
of metastatic NSCLC [52]. As well as improvements in
QoL and a reduced need for aggressive end-of-life care,
early palliative intervention prolonged survival by
∼2 months.
role of bone-targeted therapies in lung
cancer
Despite improvements in the primary treatment of lung
cancer, SREs still affect many patients and complicate the
clinical picture. Recent ESMO guidelines for staging and
treatment of NSCLC do not consider the use of bone-targeted
therapies for the prevention of SREs [3]. However, recent
National Comprehensive Cancer Network guidelines
recommend therapy with either bisphosphonates or
denosumab for patients with NSCLC [53]. Notably, a panel of
European expert physicians recommend that individuals with
NSCLC are screened for asymptomatic bone metastases at
initial disease staging and treated with bone-targeted therapy if
bone metastases are conﬁrmed [54].
Bisphosphonates have shown efﬁcacy in randomised
placebo-controlled trials for preventing and delaying SREs and
Figure 3. Estimated costs of skeletal complications in patients with lung
cancer by (A) type of SRE and (B) type of service. Values are in US$. Data
are based on Kaplan–Meier-estimated costs of SRE-related care in patients
with bone metastases arising from lung cancer who experienced at least
one SRE (n = 295) [42]. In (A), ‘other’ includes opiods/nonsteroidal anti-
inﬂammatory drugs (US$133), physical medicine (US$115), spinal cord
compression (US$77) and non-operative treatment of fractures (US$71). In
(b), ‘other’ includes skilled nursing (US$174), outpatient pharmacy (US
$133), emergency room visit (US$60), home health (US$25) and
laboratory-associated costs (US$1). Figure reproduced from Delea et al.
2004 [42] with permission from S. Karger AG, Basel.
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improving QoL in patients with solid tumours, including
NSCLC, while concomitantly preventing the increase in pain
that accompanies progression of malignant bone disease [28,
55–58]. Zoledronic acid is the bisphosphonate most widely
used for the prevention of SREs in patients with bone
metastases from advanced cancer and can be used to treat
advanced NSCLC [59]. A long-term study of 773 individuals
with NSCLC and other solid tumours (excluding breast and
prostate) revealed that fewer patients treated with zoledronic
acid 4 mg experienced at least one SRE than those taking
placebo (zoledronic acid, 39%; placebo, 46%). Furthermore,
zoledronic acid signiﬁcantly delayed the median time to ﬁrst
SRE (236 versus 155 days; P = 0.009), signiﬁcantly reduced the
annual incidence of SREs (1.74 versus 2.71; P = 0.012) and
signiﬁcantly reduced the risk of experiencing an SRE by 31%
[hazard ratio (HR) = 0.693; P = 0.003] [28]. When used in
conjunction with platinum-based chemotherapy in 32 patients
with NSCLC and bone metastases, zoledronic acid 4 mg was
recently reported to signiﬁcantly reduce pain scores and
analgesic use [60].
Clinical experience suggests that bisphosphonates are rarely
used in treatment regimens for NSCLC [61] despite evidence
that they are an effective treatment of bone metastases and
prevention of SREs in this population [28]. One of the reasons
for this may be the potential adverse effects of these agents.
Orally administered bisphosphonates are associated with
gastrointestinal intolerance, while nephrotoxicity and
osteonecrosis of the jaw are usually linked with i.v. agents
[62–64]. Owing to the potential for renal damage, careful
monitoring of renal function is required before and during
treatment with zoledronic acid [65]. Given the additional
potential for platinum-induced nephrotoxicity associated with
ﬁrst-line chemotherapy, renal monitoring may be a particularly
important consideration when using bisphosphonates in
patients with NSCLC.
An alternative bone-targeted therapy with reduced
nephrotoxicity could assist with reducing the potential
cumulative nephrotoxicity when combined with platinum-
based agents. Denosumab, administered monthly as a
subcutaneous injection (120 mg), was non-inferior to
zoledronic acid in delaying the time to ﬁrst on-study SRE
[HR = 0.84; 95% conﬁdence interval (CI) 0.71–0.98; P = 0.0007
(non-inferiority); P = 0.06 (superiority)] in patients with bone
metastases arising from solid tumours including NSCLC
(excluding breast and prostate) [66]. Denosumab also showed a
trend of delayed time to ﬁrst and subsequent SREs over
zoledronic acid [rate ratio = 0.90; 95% CI 0.77–1.04; P = 0.14
(superiority)]. Overall survival was similar between groups.
The incidence of osteonecrosis of the jaw was similarly low in
both treatment groups; however, adverse events potentially
associated with acute phase reactions and nephrotoxicity
occurred more frequently in patients treated with zoledronic
acid than denosumab. Overall, denosumab may be more
suitable than zoledronic acid for combination treatment with
platinum-based therapy in patients with NSCLC. Recently,
denosumab has been approved for prevention of SREs in
patients with solid tumours by the Australian, Canadian,
European, Japanese, Russian, Swiss and USA regulatory
authorities.
additional roles of bone-targeted
therapies
Results from recent studies suggest that bone-targeted therapies
may have actions beyond bone resorption and in reducing
SREs. In a retrospective audit of patients diagnosed with
NSCLC between 2004 and 2009, 42% presented with metastatic
bone disease [61]. Patients treated with zoledronic acid in
combination with platinum-based chemotherapy had increased
overall survival (34 weeks) relative to those treated with
chemotherapy alone (19 weeks; P = 0.01). Improvements in
survival have yet to be demonstrated prospectively.
RANKL may also trigger tumour cell proliferation [67] and
promote migration of RANK-expressing tumour cells to bone
[68]. Denosumab may therefore also have direct antitumour
effects. An exploratory analysis of data from a randomised
phase III trial in patients with bone metastases arising from
solid tumours (including NSCLC) was conducted to examine
overall survival [69]. In 702 individuals with NSCLC, overall
median survival was increased by 1.4 months in those treated
with denosumab compared with patients treated with
zoledronic acid (9.5 months denosumab, 8.1 months
zoledronic acid; HR = 0.78; 95% CI 0.65–0.94; P = 0.01). These
hypothesis-generating data suggest further prospective
evaluation is warranted.
conclusions
Bone metastases are common in lung cancer but, owing to lack
of awareness of the adverse consequences and possibly to the
relatively short survival time associated with lung cancer, they
are rarely treated until late-stage disease when patients
experience potentially debilitating SREs. Bisphosphonates
reduce the frequency of SREs and improve pain and QoL
scores in various tumour types. However, concern over
cumulative nephrotoxicity when used with ﬁrst-line platinum-
based chemotherapies may have contributed to the limited use
of bisphosphonates in patients with lung cancer. Denosumab is
a new bone-targeted therapy that is as effective as the most
widely used bisphosphonate, zoledronic acid, for reducing the
frequency of SREs in patients with lung cancer. Denosumab
may therefore be more compatible than zoledronic acid for
combination with ﬁrst-line chemotherapy for lung cancer
because dose adjustment for impaired renal function is not
required. Additional roles for bone-targeting therapies beyond
reducing SREs are under investigation.
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